We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Life Sciences

Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.



Sign up for a 7-day FREE trial today!



Latest News in Life Sciences

  • June 20, 2018

    Purdue Pharma Axes Sales Team, Lightens Focus On Opioids

    Purdue Pharma LP late Tuesday announced the elimination of its entire sales force and creation of a new business model focused less heavily on narcotic painkillers, a milestone development for the country’s most notorious seller of prescription opioids.

  • June 20, 2018

    Policy Is Changing For Technology Transfers

    The Trump administration and Congress are tightening investment restrictions and export controls to address technology transfer concerns. These measures initially focus on China, but will have broader effects on investments in the United States and transfers of emerging technologies, say attorneys with Baker McKenzie.

  • June 20, 2018

    10 Steps To Modernizing Corporate Integrity Agreements

    A recent report by the U.S. Government Accountability Office highlights the important role corporate integrity agreements play in protecting federal health care programs when federal laws are violated. Given their central role in promoting compliance, it is time for the U.S. Department of Health and Human Services’ Office of Inspector General to update its templates and approach, say attorneys with Skadden Arps Slate Meagher & Flom LLP.

  • June 19, 2018

    Former Aegerion Execs Say FDA Approval Negates FCA Case

    Former executives at Aegerion Pharmaceuticals Inc. argued Tuesday that a False Claims Act case against them ignores a federal regulatory program that gave marketers and doctors explicit permission to recommend an expensive cholesterol drug to people who did not have the rare genetic disorder it was created for.

  • June 19, 2018

    Former Akebia, Merrimack Buddies Face Insider Trading Trial

    Two former biostatistician friends at Akebia Therapeutics Inc. and Merrimack Pharmaceuticals Inc. will face securities fraud charges for allegedly cashing in on nonpublic drug trial information, a federal judge in Massachusetts said Tuesday.

See more Life Sciences news

Life Sciences

Areas of Coverage

  • AGENCIES
  • U.S. Consumer Product Safety Commission
  • U.S. Food and Drug Administration
  • U.S. Patent and Trademark Office
  • U.S. International Trade Commission
  • POLICY & REGULATION
  • Affordable Care Act
  • Federal Food, Drug, and Cosmetic Act
  • Antitrust and consumer protection controls
  • Drug and medical device lobbying
  • State and international life sciences legislation and regulation
  • ENFORCEMENT
  • Drug and medical device recalls
  • Drug safety actions
  • Pay-for-delay investigations
  • Merger reviews
  • LITIGATION
  • Patent disputes, including
  • Abbreviated New Drug Application litigation
  • Section 301 cases
  • Product safety suits over drugs and medical devices, including off-label marketing and failure-to-warn claims
  • Consumer litigation and class actions
  • Fraud and compliance suits
  • Antitrust disputes
  • Labor and employment suits
  • Shareholder and corporate governance disputes
  • Bankruptcy proceedings
  • TRANSACTIONS
  • Mergers, acquisitions, and joint ventures
  • Share buybacks and stock splits
  • Private equity deals
  • Patent-licensing agreements
  • PROFILES
  • Personnel moves
  • Profiles of life sciences practice groups

Readership

  • Life sciences lawyers at top law firms
  • Corporate counsel and compliance officers at Fortune 1000 companies
  • Executives and attorneys in the drug, biotechnology, and medical device industries
  • Information experts at law firms, agencies, and companies
  • Policymakers at federal and state agencies
  • Judges and court staff across the U.S.
  • Professors, students, and library staff at every accredited law school in the U.S.
  • Attorney and law firm marketing professionals